MY140680A
(en)
|
2002-05-20 |
2010-01-15 |
Bristol Myers Squibb Co |
Hepatitis c virus inhibitors
|
AU2005274927B2
(en)
|
2004-07-15 |
2011-11-03 |
Albany Molecular Research, Inc. |
Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
|
US7323447B2
(en)
|
2005-02-08 |
2008-01-29 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
KR101514953B1
(ko)
*
|
2005-03-08 |
2015-04-24 |
베링거 인겔하임 인터내셔날 게엠베하 |
매크로사이클릭 화합물의 제조방법
|
US7592336B2
(en)
|
2005-05-10 |
2009-09-22 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7601686B2
(en)
|
2005-07-11 |
2009-10-13 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
AR057456A1
(es)
|
2005-07-20 |
2007-12-05 |
Merck & Co Inc |
Inhibidores de la proteasa ns3 del vhc
|
JP5249028B2
(ja)
*
|
2005-07-25 |
2013-07-31 |
インターミューン・インコーポレーテッド |
C型肝炎ウイルス複製の新規大環状阻害剤
|
EA014293B1
(ru)
*
|
2005-07-29 |
2010-10-29 |
Тиботек Фармасьютикалз Лтд. |
Макроциклические ингибиторы вируса гепатита с
|
AR055395A1
(es)
|
2005-08-26 |
2007-08-22 |
Vertex Pharma |
Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
|
US7772183B2
(en)
*
|
2005-10-12 |
2010-08-10 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7741281B2
(en)
|
2005-11-03 |
2010-06-22 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
CN101336229B
(zh)
|
2005-12-23 |
2012-06-13 |
西兰岛药物有限公司 |
改性的拟赖氨酸化合物
|
US7935670B2
(en)
|
2006-07-11 |
2011-05-03 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
AU2007272839B2
(en)
|
2006-07-13 |
2012-05-24 |
Achillion Pharmaceuticals, Inc. |
4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
|
US8343477B2
(en)
|
2006-11-01 |
2013-01-01 |
Bristol-Myers Squibb Company |
Inhibitors of hepatitis C virus
|
US7772180B2
(en)
|
2006-11-09 |
2010-08-10 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
CN101568543B
(zh)
*
|
2006-11-16 |
2012-06-06 |
百时美施贵宝公司 |
大环肽作为丙型肝炎病毒抑制剂
|
US7888464B2
(en)
|
2006-11-16 |
2011-02-15 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8003604B2
(en)
|
2006-11-16 |
2011-08-23 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7763584B2
(en)
|
2006-11-16 |
2010-07-27 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
DK2468724T3
(en)
|
2006-12-21 |
2016-02-22 |
Zealand Pharma As |
Synthesis of pyrrolidine compounds
|
EP2111227A1
(fr)
*
|
2007-01-08 |
2009-10-28 |
Phenomix Corporation |
Inhibiteurs macrocycliques de la protéase du virus de l'hépatite c
|
WO2008096002A1
(fr)
*
|
2007-02-08 |
2008-08-14 |
Tibotec Pharmaceuticals Ltd. |
Phosphonates et amidophosphates macrocycliques inhibiteurs du vhc
|
EP2125113A2
(fr)
|
2007-02-26 |
2009-12-02 |
Achillion Pharmaceuticals, Inc. |
Peptides substitués par une amine tertiaire utiles comme inhibiteurs de la réplication du virus de l'hépatite c
|
US7964580B2
(en)
|
2007-03-30 |
2011-06-21 |
Pharmasset, Inc. |
Nucleoside phosphoramidate prodrugs
|
CA2686138A1
(fr)
*
|
2007-05-03 |
2008-11-13 |
Intermune, Inc. |
Inhibiteurs macrocycliques innovants de la replication du virus de l'hepatite c
|
US8178491B2
(en)
|
2007-06-29 |
2012-05-15 |
Gilead Sciences, Inc. |
Antiviral compounds
|
WO2009005690A2
(fr)
*
|
2007-06-29 |
2009-01-08 |
Gilead Sciences, Inc. |
Composés antiviraux
|
EP2162432A2
(fr)
|
2007-06-29 |
2010-03-17 |
Gilead Sciences, Inc. |
Composés antiviraux
|
SE531698C2
(sv)
|
2007-07-12 |
2009-07-07 |
Respiratorius Ab |
Nya bronkdilaterande a,b-omättade amider
|
US8293705B2
(en)
|
2007-12-21 |
2012-10-23 |
Avila Therapeutics, Inc. |
HCV protease inhibitors and uses thereof
|
US8202996B2
(en)
|
2007-12-21 |
2012-06-19 |
Bristol-Myers Squibb Company |
Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
|
US8309685B2
(en)
|
2007-12-21 |
2012-11-13 |
Celgene Avilomics Research, Inc. |
HCV protease inhibitors and uses thereof
|
KR101683559B1
(ko)
|
2007-12-21 |
2016-12-08 |
셀진 아빌로믹스 리서치, 인코포레이티드 |
Hcv 프로테아제 억제제 및 이의 용도
|
AU2008340261C1
(en)
|
2007-12-21 |
2015-12-10 |
Celgene Avilomics Research, Inc. |
HCV protease inhibitors and uses thereof
|
BRPI0821836A2
(pt)
|
2007-12-24 |
2015-06-16 |
Tibotec Pharm Ltd |
Indóis macrocíclicos como inibidores do vírus da hepatite c
|
KR101216900B1
(ko)
*
|
2008-04-11 |
2012-12-28 |
에프. 호프만-라 로슈 아게 |
복분해 반응을 위한 촉매로서의 신규 루테늄 착물
|
US8163921B2
(en)
|
2008-04-16 |
2012-04-24 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7964560B2
(en)
|
2008-05-29 |
2011-06-21 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
EP2300491B1
(fr)
|
2008-05-29 |
2016-01-06 |
Bristol-Myers Squibb Company |
Inhibiteurs du virus de l hépatite c
|
US9156812B2
(en)
|
2008-06-04 |
2015-10-13 |
Bristol-Myers Squibb Company |
Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
|
WO2010015545A1
(fr)
*
|
2008-08-07 |
2010-02-11 |
F. Hoffmann-La Roche Ag |
Procédé pour la préparation d'un macrocycle
|
US8207341B2
(en)
|
2008-09-04 |
2012-06-26 |
Bristol-Myers Squibb Company |
Process or synthesizing substituted isoquinolines
|
UY32099A
(es)
|
2008-09-11 |
2010-04-30 |
Enanta Pharm Inc |
Inhibidores macrocíclicos de serina proteasas de hepatitis c
|
EA019965B1
(ru)
|
2008-09-17 |
2014-07-30 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Комбинация ингибитора протеазы ns3 hcv с интерфероном и рибавирином
|
US8563505B2
(en)
|
2008-09-29 |
2013-10-22 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8044087B2
(en)
|
2008-09-29 |
2011-10-25 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
WO2010068760A2
(fr)
|
2008-12-10 |
2010-06-17 |
Achillion Pharmaceuticals, Inc. |
Nouveaux peptides 4-amino-4-oxobutanoyl utiles en tant qu'inhibiteurs de la réplication virale
|
US8283310B2
(en)
|
2008-12-15 |
2012-10-09 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
SG194404A1
(en)
|
2008-12-23 |
2013-11-29 |
Gilead Pharmasset Llc |
Synthesis of purine nucleosides
|
US8551973B2
(en)
|
2008-12-23 |
2013-10-08 |
Gilead Pharmasset Llc |
Nucleoside analogs
|
US8716262B2
(en)
|
2008-12-23 |
2014-05-06 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
KR101868412B1
(ko)
|
2009-02-27 |
2018-06-18 |
얀센 파마슈티칼스 인코포레이티드 |
Hcv 마크로사이클릭 저해제의 무정형 염
|
US8377962B2
(en)
|
2009-04-08 |
2013-02-19 |
Idenix Pharmaceuticals, Inc. |
Macrocyclic serine protease inhibitors
|
AU2010247735B2
(en)
|
2009-05-12 |
2015-07-16 |
Albany Molecular Research, Inc. |
Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)- 1,2,3,4-tetrahydroisoquinoline and use thereof
|
ES2446971T3
(es)
|
2009-05-12 |
2014-03-11 |
Albany Molecular Research, Inc. |
Tetrahidroisoquinolinas sustituidas con arilo, heteroarilo, y heterociclo y su uso
|
CN102595902B
(zh)
|
2009-05-12 |
2015-04-29 |
阿尔巴尼分子研究公司 |
7-([1,2,4]三唑并[1,5-a]吡啶-6-基)-4-(3,4-二氯苯基)-1,2,3,4-四氢异喹啉及其用途
|
US8618076B2
(en)
|
2009-05-20 |
2013-12-31 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
TWI576352B
(zh)
|
2009-05-20 |
2017-04-01 |
基利法瑪席特有限責任公司 |
核苷磷醯胺
|
US8232246B2
(en)
|
2009-06-30 |
2012-07-31 |
Abbott Laboratories |
Anti-viral compounds
|
DK2451438T3
(da)
|
2009-07-07 |
2014-03-10 |
Boehringer Ingelheim Int |
Farmaceutisk sammensætning til en hepatitis C-virus-roteaseinhibitor
|
US9284307B2
(en)
|
2009-08-05 |
2016-03-15 |
Idenix Pharmaceuticals Llc |
Macrocyclic serine protease inhibitors
|
JP2013505951A
(ja)
*
|
2009-09-28 |
2013-02-21 |
エフ.ホフマン−ラ ロシュ エルティーディー |
C型肝炎ウイルス複製の新規の大環状インヒビター
|
AU2010313497B2
(en)
|
2009-10-30 |
2013-08-01 |
Boehringer Ingelheim International Gmbh |
Dosage regimens for HCV combination therapy comprising BI201335, interferon alpha and ribavirin
|
WO2011091417A1
(fr)
|
2010-01-25 |
2011-07-28 |
Enanta Pharmaceuticals, Inc. |
Inhibiteurs du virus de l'hépatite c
|
US8933110B2
(en)
|
2010-01-25 |
2015-01-13 |
Enanta Pharmaceuticals, Inc. |
Hepatitis C virus inhibitors
|
CN104017020B
(zh)
|
2010-03-31 |
2017-04-12 |
吉利德制药有限责任公司 |
核苷氨基磷酸酯
|
EP2609923B1
(fr)
|
2010-03-31 |
2017-05-24 |
Gilead Pharmasset LLC |
Procede de crystallisation de (s)-isopropyl 2-(((s)-(perfluorophenoxy)(phenoxy)phosphoryl)amino)propanoate
|
EP2455068A1
(fr)
*
|
2010-11-09 |
2012-05-23 |
F. Hoffmann-La Roche AG |
Composition pharmaceutique pour le traitement d'infections par VHC
|
AU2011329233A1
(en)
|
2010-11-15 |
2013-05-23 |
Abbvie Deutschland Gmbh & Co Kg |
NAMPT and ROCK inhibitors
|
WO2012075140A1
(fr)
|
2010-11-30 |
2012-06-07 |
Pharmasset, Inc. |
Composés
|
PE20140039A1
(es)
|
2010-12-30 |
2014-03-01 |
Enanta Pharm Inc |
Inhibidores de serina proteasa de hepatitis c a base de macrociclicos de fenantridina
|
WO2012092409A2
(fr)
|
2010-12-30 |
2012-07-05 |
Enanta Phararmaceuticals, Inc |
Inhibiteurs macrocycliques de sérine protéase d'hépatite c
|
US9353100B2
(en)
|
2011-02-10 |
2016-05-31 |
Idenix Pharmaceuticals Llc |
Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
|
US8957203B2
(en)
|
2011-05-05 |
2015-02-17 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US10201584B1
(en)
|
2011-05-17 |
2019-02-12 |
Abbvie Inc. |
Compositions and methods for treating HCV
|
US8691757B2
(en)
|
2011-06-15 |
2014-04-08 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
GB201116559D0
(en)
|
2011-09-26 |
2011-11-09 |
Univ Leuven Kath |
Novel viral replication inhibitors
|
US8889159B2
(en)
|
2011-11-29 |
2014-11-18 |
Gilead Pharmasset Llc |
Compositions and methods for treating hepatitis C virus
|
MX2014015156A
(es)
|
2012-06-12 |
2015-08-06 |
Abbvie Inc |
Derivados de piridinona y piridazinona.
|
ES2613766T3
(es)
|
2012-10-19 |
2017-05-25 |
Bristol-Myers Squibb Company |
Derivados de carbamato de hexadecahidrociclopropa(e)pirrolo(1,2-a)(1,4)diazaciclopentadecinilo sustituidos con 9-metilo como inhibidores de la proteasa no estructural 3 (NS3) para el tratamiento de infecciones del virus de la hepatitis C
|
US9334279B2
(en)
|
2012-11-02 |
2016-05-10 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US9643999B2
(en)
|
2012-11-02 |
2017-05-09 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US9598433B2
(en)
|
2012-11-02 |
2017-03-21 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
WO2014070974A1
(fr)
|
2012-11-05 |
2014-05-08 |
Bristol-Myers Squibb Company |
Inhibiteurs du virus de l'hépatite c
|
JP6342922B2
(ja)
|
2013-03-07 |
2018-06-13 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
C型肝炎ウイルス阻害剤
|
CA2905433A1
(fr)
|
2013-03-14 |
2014-09-25 |
Achillion Pharmaceuticals, Inc. |
Processus innovants de production de sovaprevir
|
US9006423B2
(en)
|
2013-03-15 |
2015-04-14 |
Achillion Pharmaceuticals Inc. |
Process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof
|
MX2015013020A
(es)
|
2013-03-15 |
2016-06-10 |
Achillion Pharmaceuticals Inc |
Polimorfos de sovaprevir y metodos de fabricacion de los mismos.
|
WO2014145600A1
(fr)
|
2013-03-15 |
2014-09-18 |
Achillion Pharmaceuticals, Inc. |
Polymorphes de sel de sodium d'ach-0142684, composition les comprenant, et leur procédé de fabrication
|
NZ716840A
(en)
|
2013-08-27 |
2017-06-30 |
Gilead Pharmasset Llc |
Combination formulation of two antiviral compounds
|
WO2015103490A1
(fr)
|
2014-01-03 |
2015-07-09 |
Abbvie, Inc. |
Formes galéniques antivirales solides
|
ES2870106T3
(es)
|
2017-05-05 |
2021-10-26 |
Zealand Pharma As |
Moduladores de la comunicación intercelular de uniones comunicantes y su uso para el tratamiento de la enfermedad del ojo diabético
|